Table 2 Univariate and multivariable analysis of predictors of PFS and OS of patients treated with everolimus for mRCC
Univariate Cox regression | Multivariable Cox regression | |||
|---|---|---|---|---|
HR (95%CI) | P -value | HR (95%CI) | P -value | |
PFS | ||||
Gender | 0.67 (0.45–1.33) | 0.36 | ||
Age | 1.00 (0.98–1.02) | 0.89 | ||
Motzer prognostic group | 1.84 (1.10–3.08) | 0.02 | 1.93 (1.15–3.23) | 0.013 |
PFS on first-line therapy | 1.21 (0.69–2.12) | 0.50 | ||
Neutrophilia (Y/N) | 2.73 (1.50–4.95) | 0.001 | ||
NLR >3 vs <3 | 2.99 (1.80–4.97) | <0.001 | 2.66 (1.43–4.94) | 0.002 |
OS | ||||
Gender | 0.85 (0.45–1.60) | 0.63 | ||
Age | 0.98 (0.95–1.00) | 0.16 | ||
Motzer prognostic group | 2.54 (1.36–4.76) | 0.004 | 2.96 (1.57–5.57) | <0.001 |
PFS on first-line therapy | 1.08 (0.57–2.03) | 0.322 | ||
Neutrophilia (Y/N) | 2.08 (1.08–3.99) | 0.02 | ||
NLR >3 vs <3 | 2.45 (1.40–4.30) | <0.001 | 2.27 (1.16–4.43) | 0.003 |
